News and updates covered here include a questionable justification for the sale of two fast-growing companies by an AIM listed group. Elsewhere, there were significant contract wins for others and a hefty funds raise for one popular company. Read on here for more on this and other news.
hVIVO: another contract - it’s all about the execution
hVIVO (AIM: HVO), a specialist contract research organisation (CRO) and apparent “world leader” in testing infectious and respiratory disease products using human challenge clinical trials, announced a £6.8m contract with a leading pharmaceutical company based in Asia Pacific.
The contract covers the testing of its respiratory syncytial virus ("RSV") antiviral drug candidate, using the hVIVO RSV Human Challenge Study Model and will take…
Investor's Champion offers objective, incisive and forthright comment on quoted companies and personal finance. Our content addresses what we believe are the key issues in helping make your money go further.
Investor's Champion is a registered trade mark of Investors Champion Ltd. Investor's Champion Limited is a company registered in England and Wales under number 03577867 whose registered office is at c/o Cox Costello & Horne, 26 Main Avenue, Moor Park, England, HA6 2HJ.